[go: up one dir, main page]

MXPA06005424A - Metodos para caracterizar virus de enfermedad bursal infecciosa. - Google Patents

Metodos para caracterizar virus de enfermedad bursal infecciosa.

Info

Publication number
MXPA06005424A
MXPA06005424A MXPA06005424A MXPA06005424A MXPA06005424A MX PA06005424 A MXPA06005424 A MX PA06005424A MX PA06005424 A MXPA06005424 A MX PA06005424A MX PA06005424 A MXPA06005424 A MX PA06005424A MX PA06005424 A MXPA06005424 A MX PA06005424A
Authority
MX
Mexico
Prior art keywords
disease virus
bursal disease
methods
infectious bursal
ibdv
Prior art date
Application number
MXPA06005424A
Other languages
English (en)
Inventor
Thomas Paul Brown
Mary J Pantin-Jackwood
Original Assignee
Univ Georgia Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgia Res Found filed Critical Univ Georgia Res Found
Publication of MXPA06005424A publication Critical patent/MXPA06005424A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Evolutionary Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Caracterizacion de virus de enfermedad viral infecciosa ("IBDV") para uso en la produccion e identificacion de vacunas que proporciona la seleccion rapida de una cepa para vacuna especifica con una secuencia de IBDV mas relacionada al IBDV de interes o identificacion de una cepa nueva de IBDV.
MXPA06005424A 2003-11-13 2004-11-08 Metodos para caracterizar virus de enfermedad bursal infecciosa. MXPA06005424A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51957103P 2003-11-13 2003-11-13
PCT/US2004/037255 WO2005049794A2 (en) 2003-11-13 2004-11-08 Methods of characterizing infectious bursal disease virus

Publications (1)

Publication Number Publication Date
MXPA06005424A true MXPA06005424A (es) 2007-01-25

Family

ID=34619359

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06005424A MXPA06005424A (es) 2003-11-13 2004-11-08 Metodos para caracterizar virus de enfermedad bursal infecciosa.

Country Status (6)

Country Link
US (1) US20050214316A1 (es)
EP (1) EP1689858B1 (es)
CA (1) CA2545886A1 (es)
ES (1) ES2417019T3 (es)
MX (1) MXPA06005424A (es)
WO (1) WO2005049794A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY143506A (en) * 2004-11-05 2011-05-31 Univ Putra Malaysia Detection and distinguishing infectious bursal disease virus (ibdv) strains by molecular biology method
ES2310062B1 (es) 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
EP2347352B1 (en) * 2008-09-16 2019-11-06 Beckman Coulter, Inc. Interactive tree plot for flow cytometry data
WO2010126351A1 (en) * 2009-04-30 2010-11-04 Universiti Putra Malaysia Molecular differentiation of infectious bursal disease virus (ibdv) strains
EP2407534A1 (en) 2010-07-14 2012-01-18 Neo Virnatech, S.L. Methods and reagents for obtaining transcriptionally active virus-like particles and recombinant virions
EP3089755A1 (en) 2014-01-03 2016-11-09 Fundacion Biofisica Bizkaia VLPs, METHODS FOR THEIR OBTENTION AND APPLICATIONS THEREOF
EP3263129A1 (en) * 2016-06-29 2018-01-03 Ceva Sante Animale Duck enteritis virus and the uses thereof
CN106521037B (zh) * 2016-12-19 2019-10-01 咸阳职业技术学院 一种用于诊断FAdV/MDV/ALV/REV4重PCR检测试剂盒
RU2678870C1 (ru) * 2018-04-02 2019-02-04 Общество с ограниченной ответственностью "СП-Вет" Набор реагентов для обнаружения нуклеиновой кислоты вируса болезни Гамборо
CN111073999B (zh) * 2018-10-22 2022-08-09 四川农业大学 同步共检六种禽病毒的可视化芯片
CN110295148A (zh) * 2019-06-24 2019-10-01 四川农业大学 一种快速构建3型鸭甲肝病毒反向遗传株的方法
US20210386804A1 (en) * 2020-06-11 2021-12-16 Tibor Bakács Combination of viral superinfection therapy with subthreshold doses of nivolumab plus ipilimumab in chronic HBV patients
KR102421249B1 (ko) * 2020-08-24 2022-07-15 대한민국 국내 분리 미주형 항원변이형 닭전염성 f낭병 바이러스 및 이를 포함하는 백신조성물
US20240245739A1 (en) * 2021-05-18 2024-07-25 The Penn State Research Foundation Oncolytic virus based cancer therapy
WO2022266314A2 (en) * 2021-06-17 2022-12-22 Intervet Inc. A system and method for monitoring the effect of a herpesvirus-based vaccine in an animal population
CN115281146B (zh) * 2022-07-08 2023-06-16 山东省农业科学院家禽研究所（山东省无特定病原鸡研究中心） 一种鸡湿热下利证模型的构建方法
EP4371569A1 (en) 2022-11-16 2024-05-22 Universidad del País Vasco/Euskal Herriko Unibertsitatea Vlps against acute myeloid leukaemia

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4458630A (en) 1982-06-22 1984-07-10 The United States Of America As Represented By The Secretary Of Agriculture Disease control in avian species by embryonal vaccination
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
CA1334941C (en) 1985-05-30 1995-03-28 Ahmed Azad Azad Cloning and expression of a host-protective immunogens of ibdv
IL84154A0 (en) 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
WO1990001543A1 (fr) 1988-07-29 1990-02-22 Intracel Corporation Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5552143A (en) 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
US5614409A (en) 1989-05-30 1997-03-25 Commonwealth Scientific And Industrial Research Organisation Production of IBDV VP2 in highly immunogenic form
EP0474676A4 (en) 1989-05-30 1993-02-24 The Commonwealth Scientific And Industrial Research Organization Production of ibdv vp2 in highly immunogenic form
US5632989A (en) 1989-10-18 1997-05-27 University Of Maryland Attenuated, live vaccine for Delaware strain IBDV
GB9001766D0 (en) 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
US5595912A (en) 1990-05-04 1997-01-21 University Of Maryland College Park Specific DNA and RNA sequences associated with US IBDV variants, vector carrying DNA sequences, host carrying cloned vector, deduced amino acid sequences, vaccine and method of vaccination
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
AU672359B2 (en) 1991-03-07 1996-10-03 Virogenetics Corporation Genetically engineered vaccine strain
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US6485729B1 (en) 1993-09-13 2002-11-26 Protein Sciences Corporation Neuraminidase-supplemented compositions
FR2728795B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
FR2728794B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
FR2741806B1 (fr) 1995-11-30 1998-02-20 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus felin de type 1, notamment contre la peritonite infectieuse feline
FR2750866B1 (fr) 1996-06-27 1998-11-27 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
FR2750865B1 (fr) 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751228B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
FR2751223B1 (fr) 1996-07-19 1998-12-04 Rhone Merieux Formule de vaccin polynucleotidique felin
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
ATE198910T1 (de) 1996-10-17 2001-02-15 Oxford Biomedica Ltd Retrovirale vektoren
FR2757061B1 (fr) 1996-12-16 1999-03-26 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
FR2758986B1 (fr) 1997-01-31 1999-04-30 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
US6368603B1 (en) 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6004777A (en) 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
WO1998042743A1 (en) 1997-03-24 1998-10-01 Merial Canine ehrlichiosis immunogenic and diagnostic compositions and methods
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
FR2781159B1 (fr) 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
US6224882B1 (en) 1997-11-07 2001-05-01 Protein Science Corp. Insect cells or fractions as adjuvant for antigens
DK1895010T3 (da) 1997-12-22 2011-11-21 Oxford Biomedica Ltd Vektorer baseret på virus for infektiøs hesteanæmi (eiav)
US6506385B1 (en) 1998-04-17 2003-01-14 Embrex, Inc. Live vaccines and methods of treatment therewith
US6114112A (en) * 1998-05-21 2000-09-05 The Ohio State University Method of making immunogenic compositions for infectious bursal disease virus
WO2000012677A2 (en) * 1998-09-01 2000-03-09 The University Of Hong Kong Generation of recombinant infectious bursal disease viruses by reverse genetics technology and the use of the recombinant viruses as attenuated vaccines
CA2335391A1 (en) 1998-10-02 2000-04-13 Kenneth Walsh Akt compositions for enhancing survival of cells
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
US6528063B2 (en) 1999-01-04 2003-03-04 Rahan Meristem Recombinant vaccines against IBDV
DE60045059D1 (de) 1999-04-20 2010-11-18 Nat Inst Of Advanced Ind Scien Verfahren und Sonden zur Bestimmung der Konzentration von Nukleinsäure-Molekülen und Verfahren zur Analyse der gewonnenen Daten
BR0011732B1 (pt) 1999-06-10 2014-02-04 Vacinas de dna para animais de companhia e de esporte
US6943152B1 (en) 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
FR2796397B1 (fr) 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines
PT1090915E (pt) 1999-10-08 2009-08-03 Merial Sas Forma polimórfica b de 3-(ciclopropilmetoxi)-4-[-4-(metilsulfonil)fenil]-5,5-dimetil-5h-furan-2-ona
US6248535B1 (en) 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
ATE385808T1 (de) 1999-12-21 2008-03-15 Merial Sas Mindestens ein cryptosporidium parvum-antigen und mindestens ein antigen eines anderen darmkrankheitserregers enthaltende zusammensetzungen und impfstoffe
FR2804028B1 (fr) 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
ZA200104596B (en) 2000-06-09 2001-12-06 Akzo Nobel Nv IBDV strain for in ovo administration.
US6455595B1 (en) 2000-07-24 2002-09-24 Chevron U.S.A. Inc. Methods for optimizing fischer-tropsch synthesis
US6643653B1 (en) 2001-06-01 2003-11-04 Oracle International Corporation Method and apparatus for identifying a data sequence related to a given data sequence
FR2825280B1 (fr) 2001-06-01 2005-04-15 Merial Sas Vaccination contre le virus de l'immunodeficience feline
WO2003074552A1 (en) * 2002-03-01 2003-09-12 Akzo Nobel N.V. An infectious bursal disease virus variant

Also Published As

Publication number Publication date
CA2545886A1 (en) 2005-06-02
EP1689858B1 (en) 2013-05-15
EP1689858A4 (en) 2007-07-11
US20050214316A1 (en) 2005-09-29
EP1689858A2 (en) 2006-08-16
ES2417019T3 (es) 2013-08-05
ES2417019T8 (es) 2014-11-17
WO2005049794A2 (en) 2005-06-02
WO2005049794A3 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
MXPA06005424A (es) Metodos para caracterizar virus de enfermedad bursal infecciosa.
MXPA05013973A (es) Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos.
IL210378A0 (en) Tumor associated antigen, peptides thereof, and use of same as ati-tumor vaccines
EP1917033A4 (en) VIRUS LIKE PARTICLES AS PARAMYXOVIRUS VACCINES
WO2018104908A3 (en) Linked ligation
ATA1302001A (de) Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
WO2004111081A3 (en) Antigenic peptides of sars coronavirus and uses thereof
BR0312764A (pt) Cardiomiócitos funcionais originados de células-tronco embrionárias humanas
EP4290238A3 (en) Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
IL200747A0 (en) Subunits of the enteritis hemorrhagic virus fiber protein and uses thereof as vaccines
SG158154A1 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
PL1561811T3 (pl) Sposób wytwarzania L-treoniny przy użyciu mikroorganizmu posiadającego inaktywowany gen GalR
PT1951300E (pt) Modificação do equilíbrio de th1/th2 em vacinas da influenza fragmentadas com adjuvantes
IL180531A0 (en) Novel sequence for improving expression of nucleic acid
AU2003249059A8 (en) Use of vaccinia virus deleted for the e3l gene as a vaccine vector
MXPA01005808A (es) Cepa de virus de enfermedad bursal infecciosa para administracion en huevo.
ZA200508028B (en) Glycopegylation methods and proteins/peptides produced by the methods
GB2429711A (en) Heart and skeletal muscle inflammation (HSMI) virus
CN201734406U (zh) 方便烧烤的筷子
EP1908822A3 (en) Infectious bursal disease virus mutants and vaccines
PT2368572T (pt) Vacinas com adjuvante dotadas de antigénios não-virião preparados a partir de vírus da gripe cultivado em cultura celular
IL177903A (en) Vaccine for Infectious Stock Disease Virus and its Use
WO2002032455A3 (en) Vaccine
EP1591520A3 (en) Microorganism producing L-threonine having inactivated tyR gene, method of producing the same and method of producing L-threonine using the microorganism
GB0227274D0 (en) Probes